MEXICO: Ignyta Inc announces the determine of an underwritten public pervading of 4,285,714 shares of its common stock at a price to the public of $17.50 per share. The unpleasant profits from this offering are unsurprising to be about $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Ignyta.
Ignyta has granted the underwriters a 30-day option to purchase up to an additional 642,857 shares of common stock in connection with the offering. The offering is predictable to close on or about June 16, 2015, subject to customary closing conditionsIgnyta anticipates using the net proceeds from the offering to fund research and development activities for its development programs and for working capital and general corporate purposes Credit Suisse Securities (USA) LLC, Jefferies LLC, Leerink Partners LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering and Cantor Fitzgerald & Co. and Ladenburg Thalmann are acting as co-managers.
Ignyta, Inc., a precision oncology biotechnology company, engages in discovering or acquiring, developing, and commercializing new drugs for cancer patients. Its products pipeline comprises of entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in two clinical studies in molecularly defined patient populations for the treatment of solid tumors; and RXDX-103, a development program targeting the cell division cycle 7 related and protein kinase. The company was founded in 2011 and is based in San Diego, California General Growth Properties Inc (NYSE:GG)’s shares gained 0.53% to $26.79General Growth Properties Inc (GG) declared that it has raised its credit facility from $2 billion to $3 billion and extended the term to June 10, 2020, under existing terms and conditions
